logo
The One Crucial Question to Ask Your Eczema Patient

The One Crucial Question to Ask Your Eczema Patient

Medscape2 days ago
One of the most harmful eczema symptoms isn't visible in the clinic — it's the sleep patients lose from itching, pain, and bleeding at night.
About 43% of people with eczema have sleep problems, according to a recent study review in Archives of Dermatological Research .
'If I had only one question to ask, that's the one I would choose — how's the sleep?' said Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Feinberg School of Medicine, Northwestern Medicine, Chicago.
Here's why assessing sleep is crucial in eczema — and how to help patients rest better at night.
Why Sleep Should Be a Standard Part of Eczema Care
'People feel very alone in this, but almost everybody reports their itch is worse at night,' said Lio.
Preliminary research suggests that circadian rhythms in skin barrier function could partially explain this phenomenon. Another factor: When patients lie down to sleep, the day's responsibilities done, they may finally notice their underlying itchiness.
'People describe it like the flood gates opening,' said Zelma Chiesa Fuxench, MD, MSCE, associate professor in dermatology at Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 'All of a sudden, they're not thinking about anything else that they need to do to get through the day, and the itching is there.'
Some patients have insomnia — tossing, turning, and scratching for hours before falling asleep. Others 'fall asleep great but then wake up multiple times or wake up early, kind of miserable and itchy,' said Lio. Then it's hard to fall back asleep.
Some people scratch while sleeping, reducing sleep quality. They don't feel rested despite going to bed and rising at normal times. 'Oftentimes their skin looks terrible in the morning, and sometimes there's even blood on the sheets,' said Lio.
People with severe eczema tend to have more sleep trouble. Research suggests that tissue damage and inflammation might cause sleep disturbances, and skin barrier disruption might alter circadian rhythms and increase sensitivity to environmental triggers.
What's more, insufficient sleep can directly harm skin. 'There are studies that show just keeping people up for one night, screwing up one night of sleep, has a measurable damaging effect on the skin barrier in healthy patients,' said Lio. 'So imagine if you already have a damaged barrier and are staying up night after night. You're really in a vicious loop.'
In eczema sufferers, sleep problems can reduce quality of life and can be linked with depression, anxiety symptoms, and neurocognitive deficits. 'Understanding the impact of sleep loss is very important because of the association between lack of sleep and disease morbidity,' said Chiesa Fuxench.
Of course, poor sleep can harm patients' overall health too. Bad sleep can also become a household problem that affects parents, caregivers, and partners of people with eczema, said Chiesa Fuxench.
What to Ask Eczema Patients About Sleep
Questions about sleep can give you a glimpse into a patient's day-to-day eczema control, beyond what you can see during an appointment.
'With a very dynamic disease on the skin, we have what I'll call the 'mechanic's problem,'' said Lio. That's the phenomenon of your car's funny noise disappearing when you take it to the shop.
'People will come in looking pretty good that day, so your clinical exam might not be that impressive,' he said. You might not think the patient needs treatment adjustment until you learn about their sleep habits.
And patients might not volunteer this information — you have to ask, said Chiesa Fuxench.
Here's how:
Use a validated screening tool. Ask patients to complete a quick questionnaire with a sleep-related question before their exam. The six-question Atopic Dermatitis Control Tool asks: Over the last week, how many nights did you have trouble falling or staying asleep because of your eczema? The seven-question Patient Oriented Eczema Measure asks: Over the last week, on how many nights has your sleep been disturbed because of the eczema?When patients circle their answer, they receive a numerical score you can track over time, from zero (no problem sleeping) to four (problems every night).It's helpful to capture seven nights. If you ask patients about sleep without specifying a time frame, they might only recall the night before. Their answer might not reflect their overall sleep patterns. 'If a patient says, 'You know what, my eczema has been keeping me awake every day for the last week,' then that, to me, it's a huge exclamation point,' said Chiesa Fuxench.
Ask patients to complete a quick questionnaire with a sleep-related question before their exam. The six-question Atopic Dermatitis Control Tool asks: Over the last week, how many nights did you have trouble falling or staying asleep because of your eczema? The seven-question Patient Oriented Eczema Measure asks: Over the last week, on how many nights has your sleep been disturbed because of the eczema?When patients circle their answer, they receive a numerical score you can track over time, from zero (no problem sleeping) to four (problems every night).It's helpful to capture seven nights. If you ask patients about sleep without specifying a time frame, they might only recall the night before. Their answer might not reflect their overall sleep patterns. Ask a broad question. If you can't use a screening tool, kickstart the conversation with a question that widely connects eczema and sleep. Chiesa Fuxench often asks: Are you having trouble sleeping, or is eczema affecting your sleep in any way?
'What I did for many years was simply ask: How are you sleeping? Is it affecting your sleep? Do you find that you're sleeping OK?' said Lio. 'That's probably sufficient for getting a good sense of what's going on.'
How to Help People With Eczema Sleep Better
When eczema disturbs a patient's sleep, Lio doesn't recommend sleep medications or sedating first-generation antihistamines as first-line treatments. They don't fix the underlying problem and can cause dependency.
Focus instead on the person's skin. 'My goal is to get their skin better, to get the itch under control so that they can sleep,' he said. 'I want sleep to actually be a good measure of how we're doing.'
If the patient is new or treatment-naive, consider starting treatment. Otherwise, consider advancing them to the next step of the therapeutic ladder.
'If it's a patient who was already on therapy and they're still having trouble sleeping, then it's an opportunity for us to go back and reassess: What is happening here that you are having trouble sleeping? Is it that the medication tackles some things but not others? Do we need to reassess therapy? Do we need to be more aggressive with treatment?' said Chiesa Fuxench.
For example, if gentle cleansing and moisturizing aren't enough, consider topical therapy. If topicals aren't doing the trick, now might be the time to try systemic therapy or phototherapy, said Lio.
'This doesn't necessarily mean they need a certain kind of drug,' said Lio. 'It just means we need to do something different. We need to escalate therapy.'
Complementary therapies such as acupuncture and hypnotherapy also help some eczema patients reduce stress and sleep better, he said.
Standard sleep hygiene also applies, and a few eczema-specific bedtime habits may help:
Keep pets out of bed to reduce skin irritation from dander.
Ask your partner to give you a calming massage at night to relax before sleep.
Use silk sheets to reduce friction.
Wash your bedding every 1-2 days to remove dust mites. Use fragrance-free detergent and run the rinse cycle twice to remove soap residue.
Forgot to wash your sheets? Keep an ultraviolet C sanitizing wand nearby and run it over your bedding to kill dust mites.
Use an air purifier in your bedroom to remove dander and other irritants.
As you follow up with the patient, watch for other signs of sleep-sabotaging health problems. Ask: Are you having trouble functioning? The patient might need a referral to a mental health care provider or another specialist.
'Patients with atopic dermatitis may also have other reasons why they're having trouble sleeping,' said Chiesa Fuxench. 'We are physicians at the end of the day, and we have to look at the patient as this entire being, not just someone who has atopic dermatitis.'
Lio has consulted or advised for AbbVie Inc., Apogee Therapeutics Inc., Arcutis Biotherapeutics, Eli Lilly and Company, Galderma, Incyte Corporation, L'Oreal, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi-Aventis US LLC, Skinfix Inc.; and Verrica Pharmaceuticals Inc. He has ownership or investment interest in Alphyn Biologics Inc., Boston Skin Science LLC, Codex Labs, Concerto Biosciences, LearnHealth Inc., Medable Inc., Modernizing Medicine Inc., Soteri Skin, Stratum Biosciences, Thimble Health LLC, Verdant Scientific Inc., Yobee Care Inc. He has the right to receive payments or may receive future financial benefits for inventions or discoveries related to Theraplex.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform

Yahoo

time9 minutes ago

  • Yahoo

BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform

Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Jim Cramer on UnitedHealth: 'It Could Come Back'
Jim Cramer on UnitedHealth: 'It Could Come Back'

Yahoo

time39 minutes ago

  • Yahoo

Jim Cramer on UnitedHealth: 'It Could Come Back'

UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer shed light on. Cramer showed a slight bit of optimism toward the company as he said: 'I think UnitedHealth's going to work here… I think it's going to work. I really do. Look, I'm not a believer. I don't like the fact that they had shenanigans, but I will say this: I think that the company is run by a very good CEO. It could come back.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, care delivery, and health management services. In addition, the company offers data analytics and technology-driven solutions for individuals, employers, governments, and health systems. During the August 7 episode, when a caller inquired about the company stock, Cramer responded: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)
Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

Yahoo

time39 minutes ago

  • Yahoo

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best stocks to invest in for beginners. Piper Sandler analyst Jessica Tassan reiterated a Buy rating on UnitedHealth Group Incorporated (NYSE:UNH) on August 5, setting a price target of $280.00. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) reported that its Q2 2025 revenue underwent a $12.8 billion year-over-year growth to $111.6 billion, attributed primarily to growth within Optum and UnitedHealthcare. Earnings from operations for the quarter were $5.2 billion, while adjusted net earnings were $4.08 per share. Management reported a full year 2025 revenue outlook in the $445.5 billion to $448.0 billion range, with a full year 2025 earnings outlook of at least $14.65 per share. UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store